RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia

por Koschut, David, Ray, Debleena, Li, Zhenhua, Giarin, Emanuela, Groet, Jürgen, Alić, Ivan, Kham, Shirley Kow-Yin, Chng, Wee Joo, Ariffin, Hany, Weinstock, David M., Yeoh, Allen Eng-Juh, Basso, Giuseppe, Nižetić, Dean
Publicado 2020

Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia

por Li, Zhenhua, Lee, Shawn Hsien Ren, Chin, Winnie Hui Ni, Lu, Yi, Jiang, Nan, Lim, Evelyn Huizi, Coustan-Smith, Elaine, Chiew, Kean Hui, Oh, Bernice Ling Zhi, Koh, Grace Shimin, Chen, Zhiwei, Kham, Shirley Kow Yin, Quah, Thuan Chong, Lin, Hai Peng, Tan, Ah Moy, Ariffin, Hany, Yang, Jun J., Yeoh, Allen Eng-Juh
Publicado 2021

Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP

por Qian, Maoxiang, Zhang, Hui, Kham, Shirley Kow-Yin, Liu, Shuguang, Jiang, Chuang, Zhao, Xujie, Lu, Yi, Goodings, Charnise, Lin, Ting-Nien, Zhang, Ranran, Moriyama, Takaya, Yin, Zhaohong, Li, Zhenhua, Quah, Thuan Chong, Ariffin, Hany, Tan, Ah Moy, Shen, Shuhong, Bhojwani, Deepa, Hu, Shaoyan, Chen, Suning, Zheng, Huyong, Pui, Ching-Hon, Yeoh, Allen Eng-Juh, Yang, Jun J.
Publicado 2017